• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Clinical evaluation of ID NOW influenza A & B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology - A comp

tetano

Editor, Senior Moderator
J Infect Chemother. 2019 Sep 23. pii: S1341-321X(19)30264-8. doi: 10.1016/j.jiac.2019.08.015. [Epub ahead of print] [h=1]Clinical evaluation of ID NOW influenza A & B 2, a rapid influenza virus detection kit using isothermal nucleic acid amplification technology - A comparison with currently available tests.[/h]
Mitamura K[SUP]1[/SUP], Shimizu H[SUP]2[/SUP], Yamazaki M[SUP]3[/SUP], Ichikawa M[SUP]4[/SUP], Abe T[SUP]5[/SUP], Yasumi Y[SUP]6[/SUP], Ichikawa Y[SUP]7[/SUP], Shibata T[SUP]8[/SUP], Yoshihara M[SUP]9[/SUP], Shiozaki K[SUP]10[/SUP], Baba S[SUP]11[/SUP], Kudo Y[SUP]12[/SUP], Tokushima M[SUP]13[/SUP], Konomi Y[SUP]14[/SUP], Kawakami C[SUP]15[/SUP].
[h=3]Author information[/h] 1 Eiju General Hospital, Taito-ku, Tokyo 110-8645, Japan. Electronic address: mitamura@eijuhp.com. 2 Kawasaki City Institute for Public Health, Kawasaki, Kanagawa 210-0834, Japan. 3 Zama Children's Clinic, Zama, Kanagawa 252-0023, Japan. 4 Ichikawa Children's Clinic, Isehara, Kanagawa 259-1133, Japan. 5 Abe Children's Clinic, Yokohama, Kanagawa, 223-0051, Japan. 6 Yasumi Hospital, Morioka, Iwate 028-4125, Japan. 7 Ichikawa Clinic, Fukushima-shi, Fukushima 960-0112, Japan. 8 Futaba Children's Clinic, Ushiku, Ibaraki 300-1207, Japan. 9 Junseikai Yoshihara Clinic, Takasaki, Gunma 370-3524, Japan. 10 Shiozaki Clinic, Wakayama, Wakayama 640-8482, Japan. 11 Wakaayukai Baba Clinic, Nagaokakyou, Kyoto 617-0814, Japan. 12 Kudo Clinic, Kakogawa, Hyogo 675-0018, Japan. 13 Maebashi Kita Hospital, Maebashi, Gunma 371-0054, Japan. 14 Jinjikai Takahashi Clinic, Bando, Ibaraki 306-0631, Japan. 15 Yokohama City Institute of Public Health, Yokohama, Kanagawa 236-0051, Japan.

[h=3]Abstract[/h] In this study, we evaluated the performance of ID NOW Influenza A & B 2 (ID NOW 2), a rapid molecular point-of-care test for influenza within 13 min, in comparison with currently available tests. A total of 254 nasopharyngeal swabs (NPS) and 271 nasopharyngeal aspirates (NPA) collected from 373 children and 152 adults with influenza-like illness were tested using ID NOW 2, viral culture, rapid antigen detection test, and loop-mediated isothermal amplification test to evaluate the sensitivity and specificity compared with real-time reverse transcription polymerase chain reaction as the reference method. The sensitivities of ID NOW 2 for influenza A were 95.9% and 95.7% in NPS and NPA, respectively, and for influenza B were 100% and 98.7% in NPS and NPA, respectively. The specificity was 100% for both influenza A and influenza B in NPS and NPA. Sensitivity of each test method reflected the difference of analytical sensitivity among the tests, and ID NOW 2 was not affected by time after illness onset and patient age. In conclusion, ID NOW 2 demonstrated a high sensitivity and specificity that is useful for diagnosis of influenza in the clinical setting and infection control.
Copyright ? 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.


[h=4]KEYWORDS:[/h] ID NOW influenza A & B 2; Influenza; Isothermal nucleic acid amplification; Point-of-care testing; Rapid antigen detection test

PMID: 31558351 DOI: 10.1016/j.jiac.2019.08.015
 
Back
Top Bottom